Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells.

Acute myeloid leukemia (AML) Autophagy Chronic lymphoid leukemia Drug design HDAC10 Histone deacetylases (HDAC) Ligand docking Lysosomes

Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
15 Apr 2022
Historique:
received: 21 01 2022
revised: 07 03 2022
accepted: 08 03 2022
pubmed: 21 3 2022
medline: 13 4 2022
entrez: 20 3 2022
Statut: ppublish

Résumé

Histone deacetylases (HDACs) are a family of 18 epigenetic modifiers that fall into 4 classes. Histone deacetylase inhibitors (HDACi) are valid tools to assess HDAC functions. HDAC6 and HDAC10 belong to the class IIb subgroup of the HDAC family. The targets and biological functions of HDAC10 are ill-defined. This lack of knowledge is due to a lack of specific and potent HDAC10 inhibitors with cellular activity. Here, we have synthesized and characterized piperidine-4-acrylhydroxamates as potent and highly selective inhibitors of HDAC10. This was achieved by targeting the acidic gatekeeper residue Glu274 of HDAC10 with a basic piperidine moiety that mimics the interaction of the polyamine substrate of HDAC10. We have confirmed the binding modes of selected inhibitors using X-ray crystallography. Promising candidates were selected based on their specificity by in vitro profiling using recombinant HDACs. The most promising HDAC10 inhibitors 10c and 13b were tested for specificity in acute myeloid leukemia (AML) cells with the FLT3-ITD oncogene. By immunoblot experiments we assessed the hyperacetylation of histones and tubulin-α, which are class I and HDAC6 substrates, respectively. As validated test for HDAC10 inhibition we used flow cytometry assessing autolysosome formation in neuroblastoma and AML cells. We demonstrate that 10c and 13b inhibit HDAC10 with high specificity over HDAC6 and with no significant impact on class I HDACs. The accumulation of autolysosomes is not a consequence of apoptosis and 10c and 13b are not toxic for normal human kidney cells. These data show that 10c and 13b are nanomolar inhibitors of HDAC10 with high specificity. Thus, our new HDAC10 inhibitors are tools to identify the downstream targets and functions of HDAC10 in cells.

Identifiants

pubmed: 35306288
pii: S0223-5234(22)00174-X
doi: 10.1016/j.ejmech.2022.114272
pmc: PMC9007901
mid: NIHMS1788231
pii:
doi:

Substances chimiques

Histone Deacetylase Inhibitors 0
HDAC10 protein, human EC 3.5.1.98
Histone Deacetylase 1 EC 3.5.1.98
Histone Deacetylase 6 EC 3.5.1.98
Histone Deacetylases EC 3.5.1.98

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114272

Subventions

Organisme : NIGMS NIH HHS
ID : P30 GM124165
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM049758
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR029205
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Eur J Med Chem. 2020 Aug 15;200:112338
pubmed: 32497960
J Med Chem. 2019 May 9;62(9):4426-4443
pubmed: 30964290
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
pubmed: 20057044
Biochemistry. 2021 Feb 2;60(4):303-313
pubmed: 33449614
Cell Chem Biol. 2022 Mar 17;29(3):398-411.e4
pubmed: 34762849
Nat Commun. 2017 May 18;8:15368
pubmed: 28516954
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Acta Crystallogr D Biol Crystallogr. 2013 Jul;69(Pt 7):1204-14
pubmed: 23793146
ChemMedChem. 2012 Jul;7(7):1256-66
pubmed: 22628266
Medchemcomm. 2015 Apr 1;6(4):613-618
pubmed: 26005563
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):235-42
pubmed: 21460441
J Med Chem. 2010 Apr 8;53(7):2719-40
pubmed: 20131845
PLoS Pathog. 2013;9(9):e1003645
pubmed: 24086136
Arch Toxicol. 2018 Jun;92(6):2119-2135
pubmed: 29589053
Arch Toxicol. 2018 Aug;92(8):2649-2664
pubmed: 29947893
Nat Commun. 2020 Jun 26;11(1):3258
pubmed: 32591533
Methods Mol Biol. 2016;1436:129-45
pubmed: 27246213
Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):E2592-601
pubmed: 23801752
Clin Cancer Res. 2017 May 15;23(10):2542-2555
pubmed: 27358484
J Med Chem. 2017 Dec 28;60(24):10188-10204
pubmed: 29190092
Cancers (Basel). 2019 Sep 26;11(10):
pubmed: 31561534
ALTEX. 2018 Dec 14;36(2):277-288
pubmed: 30570667
Methods Mol Biol. 2017;1510:355-364
pubmed: 27761834
Biochem Biophys Res Commun. 2020 Feb 26;523(1):246-252
pubmed: 31862140
Biochemistry. 2018 Jun 5;57(22):3105-3114
pubmed: 29533602
Methods Mol Biol. 2017;1510:3-10
pubmed: 27761809
J Med Chem. 2018 Apr 26;61(8):3454-3477
pubmed: 29589441
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Mol Cell Biol. 2008 Mar;28(5):1688-701
pubmed: 18180281
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):271-81
pubmed: 21460445
Sci Rep. 2018 Jul 3;8(1):10039
pubmed: 29968769
Eur J Med Chem. 2018 May 25;152:329-357
pubmed: 29738953
Front Cell Dev Biol. 2020 Sep 29;8:576946
pubmed: 33117804
J Med Chem. 2021 Jun 24;64(12):8486-8509
pubmed: 34101461
Cancer Biol Ther. 2015;16(7):1005-13
pubmed: 25985143
ACS Chem Biol. 2020 Aug 21;15(8):2154-2163
pubmed: 32659072
Oncology. 2011;81(5-6):325-9
pubmed: 22237050
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Epigenetics. 2012 Dec 1;7(12):1403-12
pubmed: 23108383
Trends Pharmacol Sci. 2009 Dec;30(12):647-55
pubmed: 19892411
Cells. 2021 Oct 20;10(11):
pubmed: 34831036
Br J Haematol. 2009 Nov;147(4):507-14
pubmed: 19747365
Cancers (Basel). 2019 Nov 14;11(11):
pubmed: 31739588
Sci Rep. 2020 Jan 16;10(1):424
pubmed: 31949209

Auteurs

Patrik Zeyen (P)

Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg, Wolfgang-Langenbeck-Str. 2-4, 06120, Halle/Saale, Germany.

Yanira Zeyn (Y)

Institute of Toxicology, Johannes-Gutenberg University of Mainz, Obere Zahlbacher Str. 67, 55131, Mainz, Germany.

Daniel Herp (D)

Institute of Pharmaceutical Sciences, Albert-Ludwigs University of Freiburg, Albertstraße 25, 79104, Freiburg, Germany.

Fereshteh Mahmoudi (F)

Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg, Wolfgang-Langenbeck-Str. 2-4, 06120, Halle/Saale, Germany.

Talha Z Yesiloglu (TZ)

Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg, Wolfgang-Langenbeck-Str. 2-4, 06120, Halle/Saale, Germany.

Frank Erdmann (F)

Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg, Wolfgang-Langenbeck-Str. 2-4, 06120, Halle/Saale, Germany.

Matthias Schmidt (M)

Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg, Wolfgang-Langenbeck-Str. 2-4, 06120, Halle/Saale, Germany.

Dina Robaa (D)

Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg, Wolfgang-Langenbeck-Str. 2-4, 06120, Halle/Saale, Germany.

Christophe Romier (C)

Université de Strasbourg, CNRS, INSERM, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Département de Biologie Structurale Intégrative, 67404, Illkirch Cedex, France.

Johannes Ridinger (J)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.

Corey J Herbst-Gervasoni (CJ)

Roy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania Philadelphia, PA, 19104-6323, USA.

David W Christianson (DW)

Roy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania Philadelphia, PA, 19104-6323, USA.

Ina Oehme (I)

Hopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.

Manfred Jung (M)

Institute of Pharmaceutical Sciences, Albert-Ludwigs University of Freiburg, Albertstraße 25, 79104, Freiburg, Germany.

Oliver H Krämer (OH)

Institute of Toxicology, Johannes-Gutenberg University of Mainz, Obere Zahlbacher Str. 67, 55131, Mainz, Germany. Electronic address: okraemer@uni-mainz.de.

Wolfgang Sippl (W)

Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg, Wolfgang-Langenbeck-Str. 2-4, 06120, Halle/Saale, Germany. Electronic address: wolfgang.sippl@pharmazie.uni-halle.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH